Company intelligence / Profile preview

ACT Biotech Inc

San Francisco, California, United Statesepa.gov ↗

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

ACT Biotech is a privately held biopharmaceutical company focused on developing and commercializing targeted oral therapies for cancer. Its lead program, Telatinib—an oral kinase inhibitor targeting multiple angiogenesis-related receptors—has reached Phase II clinical trials with encouraging interim results and received Orphan Drug status from the FDA. Other pipeline assets are at earlier stages.

Therapeutic areas: Oncology
Modalities: Small molecules (oral kinase inhibitors)
Industry: Biotech

Drug pipeline

4 assets

Telatinib

Phase 2

Indications: Gastric cancer

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ACT Biotech Inc.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACT Biotech Inc.

Explore the full profile